MDT

85.26

-0.95%↓

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

Начало・Списък с акции・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Отворен

СекторЗдравеопазване

3.71 2.77

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.51

Максимум

3.74

Ключови измерители
By Trading Economics
Приходи	4.1M -5.7M
Служители	34
EBITDA	3.1M -6.8M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+449.45% upside

Дивиденти
By Dow Jones
Следващи печалби	12.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-100M 288M
Предишно отваряне	0.94
Предишно затваряне	3.71

Настроения в новините

By Acuity

20%

80%

35 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

8.275 / 9.312 Подкрепа & съпротива

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

19.04.2026 г., 23:48 ч. UTC

Значими събития в новините

Crude Oil, Refined Product Prices Moving Higher Amid Renewed Tensions in Strait of Hormuz -- OPIS

19.04.2026 г., 23:36 ч. UTC

Значими събития в новините

NAB Raises Provisions as Australian Banks Face Iran Risks -- Update

19.04.2026 г., 22:47 ч. UTC

Значими събития в новините

National Australia Bank Adds $215 Million in Iran-Driven Credit Provisions

19.04.2026 г., 21:14 ч. UTC

Значими събития в новините

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

19.04.2026 г., 21:14 ч. UTC

Значими събития в новините

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

19.04.2026 г., 23:49 ч. UTC

Пазарно говорене

Значими събития в новините

Gold, Silver Decline Amid Renewed Inflation Concerns -- Market Talk

19.04.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

19.04.2026 г., 23:38 ч. UTC

Значими събития в новините

U.A.E. Asks U.S. About a Wartime Financial Lifeline -- Update

19.04.2026 г., 23:36 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Climbs on Renewed Tensions Over Strait of Hormuz -- Market Talk

19.04.2026 г., 23:12 ч. UTC

Значими събития в новините

Spot Gold Falls 1.2%, Spot Silver Drops 1.6% on Renewed Middle East Tensions

19.04.2026 г., 23:10 ч. UTC

Значими събития в новините

Front-Month Brent Crude Oil Futures Rise 5.8% to $95.64 per Barrel

19.04.2026 г., 23:09 ч. UTC

Значими събития в новините

Front-Month WTI Crude Oil Futures Climb 7.2% to $89.86 per Barrel

19.04.2026 г., 23:08 ч. UTC

Значими събития в новините

Front-Month Crude Oil Futures Climb on Renewed Tensions Over Strait of Hormuz

19.04.2026 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly Nears Deal for Cancer Biotech -- WSJ

19.04.2026 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

Announcement Could Come As Soon As Monday, Sources Say -- WSJ

19.04.2026 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

Deal Expected to Be Worth Over $2B Plus Additional Milestones, Sources Say -- WSJ

19.04.2026 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly Nears Deal for Kelonia Therapeutics, Sources Say -- WSJ

19.04.2026 г., 20:03 ч. UTC

Значими събития в новините

U.A.E. Central Bank Governor Khaled Mohamed Balama Raised Swap Idea With Treasury Secretary Scott Bessent in Washington -- WSJ

19.04.2026 г., 20:03 ч. UTC

Значими събития в новините

Emiratis Portrayed Swap Proposal as Precautionary and Preliminary in Case Iran War Drags On -- WSJ

19.04.2026 г., 20:03 ч. UTC

Значими събития в новините

The U.A.E. Has Opened Talks with U.S. for Currency Swap -- WSJ

19.04.2026 г., 20:03 ч. UTC

Значими събития в новините

U.A.E. Asks U.S. for a Wartime Financial Lifeline -- WSJ

18.04.2026 г., 01:00 ч. UTC

Значими събития в новините

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

17.04.2026 г., 22:58 ч. UTC

Печалби

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17.04.2026 г., 21:32 ч. UTC

Пазарно говорене

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17.04.2026 г., 21:22 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

17.04.2026 г., 21:22 ч. UTC

Пазарно говорене

Moody's Downgrades Belgium to A1 -- Market Talk

17.04.2026 г., 20:52 ч. UTC

Печалби

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

17.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

17.04.2026 г., 20:29 ч. UTC

Печалби

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

449.45% нагоре

12-месечна прогноза

Среден 20 USD 449.45%

Висок 20 USD

Нисък 20 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Anavex Life Sciences Corp през последните 3 месеца.

Техническа оценка

By Trading Central

8.275 / 9.312Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

35 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.